- Home
- GNLX vs HRTX Comparison
GNLX vs HRTX Comparison
Compare GNLX & HRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GNLX | HRTX |
|---|---|---|
| Founded | 2001 | 1983 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 110.4M | 90.1M |
| IPO Year | 2022 | 2007 |
Fundamental Metrics
Financial Performance| Metric | GNLX | HRTX |
|---|---|---|
| Price | $2.54 | $0.33 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 2 |
| Target Price | ★ $17.25 | $4.50 |
| AVG Volume (30 Days) | 307.9K | ★ 2.6M |
| Earning Date | 05-12-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 9.47 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $8,000.00 | ★ $154,904,000.00 |
| Revenue This Year | N/A | $15.28 |
| Revenue Next Year | N/A | $20.29 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 7.36 |
| 52 Week Low | $2.29 | $0.30 |
| 52 Week High | $8.54 | $1.58 |
Technical Indicators
Market Signals| Indicator | GNLX | HRTX |
|---|---|---|
| Relative Strength Index (RSI) | 42.93 | 42.05 |
| Support Level | $2.51 | $0.30 |
| Resistance Level | $2.95 | $0.34 |
| Average True Range (ATR) | 0.15 | 0.02 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 28.57 | 57.74 |
Price Performance
Historical ComparisonAbout GNLX Genelux Corporation
Genelux Corp is a late-stage biopharmaceutical firm focused on developing oncolytic viral immunotherapies for cancer. Its pipeline includes clinical and preclinical candidates designed to target tumor cells and stimulate an immune response against tumor-specific antigens. The company is focused on the development of next-generation oncolytic viral immunotherapies that are designed to generate a personalized multi-prong attack to overwhelm a tumor's sophisticated defense mechanisms.
About HRTX Heron Therapeutics Inc.
Heron Therapeutics Inc is a commercial-stage biotechnology company. The company is focused on improving the lives of patients by developing treatments and commercializing therapeutic solutions to address some of the unmet patient needs. The company's product portfolio consists of APONVIE, SUSTOL, ZYNRELEF, and CINVANTI.